| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/24/2003 | WO2003091274A3 Use of alpha-s2 casein precursor-derived peptided |
| 12/24/2003 | WO2003090662A3 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 12/24/2003 | WO2003089593A3 Adjuvant enhanced immunotherapy |
| 12/24/2003 | WO2003087298A3 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| 12/24/2003 | WO2003083113A3 Growth regulating proteins |
| 12/24/2003 | WO2003083080A3 Mixed- cell gene therapy |
| 12/24/2003 | WO2003082248A3 Taste masked compositions of erythromycin a and derivatives thereof |
| 12/24/2003 | WO2003079020A3 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
| 12/24/2003 | WO2003076464A3 Mutagenesis of aspergillus fungi and identification of genes essential for growth |
| 12/24/2003 | WO2003075951A3 Novel application of vaccination against tnf-alpha |
| 12/24/2003 | WO2003073097A9 Methods for isolating ligands e.g. t cell epitopes |
| 12/24/2003 | WO2003072741A3 Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| 12/24/2003 | WO2003072598A3 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases |
| 12/24/2003 | WO2003072050A3 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity |
| 12/24/2003 | WO2003070914A3 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/24/2003 | WO2003068224A3 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases |
| 12/24/2003 | WO2003066845A3 Bacteriophage lysin |
| 12/24/2003 | WO2003066048A3 Use of 15-lipoxygenase inhibitors for treating and preventing bone loss |
| 12/24/2003 | WO2003064685A3 Genetic polymorphisms in the preprotachykinin gene |
| 12/24/2003 | WO2003062431A3 Production of epi-hne-4 comprising reduction of improperly processed form |
| 12/24/2003 | WO2003055917A3 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
| 12/24/2003 | WO2003047611A3 Ptp10d, tec and edtp involved in triglycerid-metabolism |
| 12/24/2003 | WO2003045981A3 Concentrating aqueous fractions of lisinopril by reverse osmosis |
| 12/24/2003 | WO2003045416A3 Antiphlogistic agent and the use thereof |
| 12/24/2003 | WO2003040294A3 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 12/24/2003 | WO2003040174A3 Substituted amino ketone compounds |
| 12/24/2003 | WO2003039454A3 Beta-secretase inhibitors and methods of use |
| 12/24/2003 | WO2003038095A3 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents |
| 12/24/2003 | WO2003037920A3 Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration |
| 12/24/2003 | WO2003037362A3 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 12/24/2003 | WO2003037296A3 Methods and dosage forms for improving the bioavailability of therapeutic agents |
| 12/24/2003 | WO2003037267A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 12/24/2003 | WO2003035862A3 Regulation of human arginase signature-containing protein |
| 12/24/2003 | WO2003035137A3 Method and apparatus for dispensing inhalator medicament |
| 12/24/2003 | WO2003033709A3 Regulation of human serine/threonine protein kinase |
| 12/24/2003 | WO2003033661A8 Methods of using 279, a human g protein-coupled receptor |
| 12/24/2003 | WO2003032963A3 Method of reducing type 2 diabetes in high risk patients |
| 12/24/2003 | WO2003032900A3 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 12/24/2003 | WO2003018626A3 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton |
| 12/24/2003 | WO2003016329A3 Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| 12/24/2003 | WO2003014293A3 Novel polypeptide analogs and fusions and their methods of use |
| 12/24/2003 | WO2003014078A3 Muc7d1 peptides as antifungal and antibacterial agents |
| 12/24/2003 | WO2003009871A3 Inhibitors of plasminogen activator inhibitor for decreasing body mass |
| 12/24/2003 | WO2003006491A3 Peptide-based compounds for targeting intergin receptors |
| 12/24/2003 | WO2003002061B1 Compositions and methods for treating atherosclerosis |
| 12/24/2003 | WO2003000235A9 Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| 12/24/2003 | WO2003000196A3 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 12/24/2003 | WO2003000113A3 Compositions and methods for the diagnosis and treatment of tumor |
| 12/24/2003 | WO2002102990A8 Fibroblast growth factor and nucleic acid encoding same |
| 12/24/2003 | WO2002102321A3 Novel proteins and nucleic acids encoding same |
| 12/24/2003 | WO2002092764A3 Transgenic animal model of bone mass modulation |
| 12/24/2003 | WO2002090542A3 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |
| 12/24/2003 | WO2002083851A3 Vegf fusion proteins |
| 12/24/2003 | WO2002081703A3 Mitogenic oxygenase regulators |
| 12/24/2003 | WO2002077186A3 Human secreted proteins |
| 12/24/2003 | WO2002074955A3 Oligonucleotides for regulating the gene coding for tnf$g(a) and/or genes controlled thereby and use thereof |
| 12/24/2003 | WO2002068676A3 METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING |
| 12/24/2003 | WO2002068595A8 Mono-and diacylglycerol acyltransferases and methods of use thereof |
| 12/24/2003 | WO2002066601A3 Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam2 |
| 12/24/2003 | WO2002064840A3 Methods for identifying compounds that inhibit or reduce ptp1b expression |
| 12/24/2003 | WO2002057435A3 Bifunctional fusion proteins with glucocerebrosidase activity |
| 12/24/2003 | WO2002057303A3 Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides |
| 12/24/2003 | WO2002048361A3 Novel secreted proteins and their uses |
| 12/24/2003 | WO2002047611A3 Cddo-compounds and combination therapies thereof |
| 12/24/2003 | WO2002046228A3 Receptor for b. anthracis toxin |
| 12/24/2003 | WO2002038730A3 Novel human potassium channel beta subunit |
| 12/24/2003 | WO2001085193A8 Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
| 12/24/2003 | WO2001052878A8 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/24/2003 | DE20316269U1 Composition for e.g. general cosmetic purposes or sunscreens contains an osmolyte together with a liposome containing a DNA repair enzyme |
| 12/24/2003 | CN2593786Y Nano medicines against AIDS and hepatitis B |
| 12/24/2003 | CN1463270A Disulfide prodrugs and linkers and stablizers useful therefore |
| 12/24/2003 | CN1462634A Method of producing tables of biology salcium with multienzyme |
| 12/24/2003 | CN1462633A Method of preparing mouth sprays dosage with multienzyme |
| 12/24/2003 | CN1132012C Detection and treatment of cancer |
| 12/24/2003 | CN1132011C Method for determining ready compound able to regulate cell proliferative diseases |
| 12/24/2003 | CN1131872C Modified factor VII |
| 12/24/2003 | CN1131712C Colostrinin and use thereof |
| 12/24/2003 | CA2490021A1 Inhibition of t cell activation by butyrophilin 4 or b7-l1 |
| 12/24/2003 | CA2489724A1 Immunogenic conjugates |
| 12/24/2003 | CA2489645A1 Pokeweed antiviral protein polypeptides with antiviral activity |
| 12/24/2003 | CA2489605A1 Oxaliplatin anti-resistance agent |
| 12/24/2003 | CA2489463A1 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions |
| 12/24/2003 | CA2489454A1 Antibacterial amide macrocycles |
| 12/24/2003 | CA2489323A1 Treatment of non-alcoholic fatty liver disease |
| 12/24/2003 | CA2489296A1 Methods for the identification of allo-antigens and their use for cancer therapy and transplantation |
| 12/24/2003 | CA2489250A1 Composition comprising viscous fibers and viscosity-lowering proteins |
| 12/24/2003 | CA2489244A1 Treatment of serious infections and septic shock |
| 12/24/2003 | CA2489224A1 Novel polynucleotides encoding lamprey gnrh-iii |
| 12/24/2003 | CA2489095A1 Aspartyl protease inhibitors |
| 12/24/2003 | CA2488896A1 Multifunctional polypeptides |
| 12/24/2003 | CA2488879A1 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases |
| 12/24/2003 | CA2488876A1 Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets |
| 12/24/2003 | CA2488872A1 Antifungal parenteral products |
| 12/24/2003 | CA2488821A1 Methods and compositions for grafting functional loops into a protein |
| 12/24/2003 | CA2488643A1 Coated particles, methods of making and using |
| 12/24/2003 | CA2488505A1 Compositions and methods for softening, thinning and removing hyperkeratotic tissue |
| 12/24/2003 | CA2488423A1 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation |
| 12/24/2003 | CA2487809A1 Aptamer-toxin molecules and methods for using same |
| 12/24/2003 | CA2486649A1 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain |
| 12/24/2003 | CA2485751A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions |